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Sex differences in leukocyte 
profile in ST-elevation myocardial 
infarction patients
Irene V. van Blokland, Hilde E. Groot, Tom Hendriks, Solmaz Assa & Pim van der Harst✉
Background: Whether sex differences exist in the inflammatory response after ST-elevation myocardial 
infarction (STEMI) remains to be elucidated. We studied leukocyte profiles and their prognostic 
value in men and women presenting with STEMI. Methods: From a total of 552 consecutive STEMI 
patients, blood samples were collected at hospital admission. Linear regression was used to assess the 
relationship between leukocyte profiles and enzymatic infarct size. Cox regression was used to assess 
the association between leukocyte profiles and one-year mortality. Results: Women presented with 
higher lymphocyte counts (2.3·109 cells/L (IQR 1.6–3.1) vs. 1.8·109 cells/L (IQR 1.4–2.5), p = 3.00 · 10−4) 
and percentages (21.1% (IQR 14.4–28.1) vs. 17.1% (IQR 12.3–24.3), p = 0.004). Lymphocyte to 
monocyte ratio (LMR) was also higher in women (3.25 (IQR 2.56–4.5) vs. 2.68 (IQR 2.08–3.59), 
p = 7.28 · 10−7). Higher LMR was associated with lower peak CK-MB (β = −0.27 (95% CI: −0.50, −0.03), 
p = 0.026), lower peak troponin T (β = −0.45 (95% CI: −0.77, −0.13), p = 0.006) and lower one-year 
mortality risk (HR 0.35 (95% CI: 0.13, 0.96), p = 0.042). Conclusion: At admission for STEMI, women 
present with higher lymphocyte count and LMR. Higher LMR is associated with smaller infarct size and 
decreased one-year mortality risk and could be used as a biomarker to predict outcome.
Even though our knowledge of the pathophysiology of acute ST-elevation myocardial infarction (STEMI) has 
substantially increased over the past decades and inflammation showed to be an important player, the inflamma-
tory mechanisms after STEMI remain, in part, to be determined.
In the inflammatory response after STEMI, apoptotic cardiomyocytes attract inflammatory cells to the 
ischemic tissue initiating cardiac repair and remodelling1. In the early stages, these inflammatory cells mostly 
consist of neutrophils while mononuclear cells as macrophages dominate as the inflammation progresses. 
Concurrently, the inflammatory cells secrete a variety of interleukins, which activate cardiac fibroblasts and ini-
tiate scar tissue formation2–4. Excess scar tissue may impair cardiac function, leading to an increased risk of 
developing heart failure3. Limiting scar tissue formation could therefore theoretically aid in reducing long-term 
consequences of the acute inflammatory response.
The extent of the immune response may be determined by the number and type of circulating immune cells5. 
The inflammatory response differs substantially between sexes where women are known to mount stronger innate 
and adaptive immune response compared to men6. This variation may be caused by steroid hormones, which 
are known to affect survival and differentiation of immune cells5. In general, oestrogens serve both pro- and 
anti-inflammatory roles7, whilst androgens have mainly anti-inflammatory effects6,8. Taking this into consid-
eration, we might expect sex-specific differences in leukocyte profiles in STEMI patients. An improved under-
standing of these differences may aid in optimising sex-specific treatment of STEMI patients and improve risk 
stratification.
Recently, inflammation has been investigated in regard to the prognosis of STEMI patients9. The lymphocyte 
to monocyte ratio (LMR) has been regarded as a marker of inflammation which is related to coronary artery 
disease10,11. A lower LMR is thought to predict a worse prognosis as it is linked to higher mortality after STEMI. 
Furthermore, a lower LMR has recently been shown to be associated with a higher risk of having no-reflow 
after percutaneous coronary intervention (PCI) in STEMI patients12. In this study, we aimed to study differences 
between leukocyte profiles in men and women presenting with STEMI. We furthermore aimed to identify poten-
tial determinants of leukocyte profiles and study the prognostic value of LMR after STEMI in both sexes.
University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The 
Netherlands. ✉email: p.van.der.harst@umcg.nl
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Results
Baseline characteristics. Baseline characteristics for women and men are shown in Table 1. Of the total 
population, 27% were women and the average age was 67 ± 12 years in women and 63 ± 12 years in men. The 
prevalence of cardiovascular risk factors was not significantly different between sexes, except for smoking hab-
its (p = 0.001). Half of the women had hypertension, and 39% had hyperlipidemia. Previous stroke was more 
common in men (5% vs. 2%, p = 0.045). Women presented more often with a right coronary artery stenosis 
than men (51% vs. 38%, p = 0.004), whereas the left anterior descending artery (LAD) was more commonly 
the culprit vessel in men (41% vs 35%, p = 0.004). Women presented with higher levels of high sensitivity 
C-reactive protein (hsCRP) (3.4 mg/L, interquartile range (IQR) 1.6–7.8 vs. 2.2 mg/L, IQR 1.1–4.7, p = 0.004) and 
higher levels of N-terminal pro brain natriuretic peptide (NT-proBNP) (191 U/L, IQR 84–727 vs. 109 U/L, IQR 
48–311, p = 3.78 ∙ 10−6). Furthermore, women had higher levels of total cholesterol (5.3 mmol/L, IQR 4.4–6.0, vs. 
4.9 mmol/L, IQR 4.3–5.7, p = 0.012) and higher levels of high density lipoprotein (HDL) cholesterol (1.3 mmol/L, 
IQR 1.1–1.6, vs. 1.1 mmol/L, IQR 0.9–1.3, p = 1.24 ∙ 10−11). Peak values of CK, CK-MB and Troponin T did not 
differ between sexes. Medication use at admission was also similar between men and women (Supplementary 
Table 1).
Baseline levels of immune cell count in women and men post-STEMI. Women presented with 
higher lymphocyte count and percentages compared to men (2.3·109cells/L, IQR 1.6–3.1 vs. 1.8·109cells/L, IQR 
1.4–2.5, p = 3.00 ∙ 10−4; 21.1%, IQR 14.4–28.1 vs. 17.1%, IQR 12.3–24.3, p = 0.004, respectively) (Fig. 1). LMR 
was also higher in women compared to men (3.25(IQR 2.56–4.5) vs. 2.68(IQR 2.08–3.59), p = 7.28 ∙ 10–7). Men 
presented with higher percentages of monocytes (6.5%, IQR 5.3–8.0 vs. 6.0%, IQR 4.7–7.4, p = 0.007) and eosin-
ophils (1.2%, IQR 0.5–2.0 vs. 0.9%, IQR 0.5–1.6, p = 0.043).
Predictors of immune cells. After multivariate adjustment, percentages of lymphocytes were inde-
pendently associated with sex (β 0.16, 95% CI 0.05–0.27, p = 0.006), hsCRP (β −0.06, 95% CI −0.10–0.02, 
p = 0.002), HbA1c (β −2.29, 95% CI −4.43–0.14, p = 0.037) and triglycerides (β 0.14, 95% CI 0.06–0.22, 
p = 0.020) (Supplementary Table 2). Percentages of monocytes were independently associated with sex (β −0.89, 
95% CI −1.39–0.40, p = 0.001), age (β 0.10, 95% CI 0.01–0.20, p = 0.043), triglycerides (β 0.36, 95% CI 0.04–
0.68, p = 0.028), NT-proBNP (β 0.18, 95% CI 0.02–0.35, p = 0.028) and peak CK (β −0.22, 95% CI −0.39–0.06, 
p = 0.008). Percentages of eosinophils were independently associated with sex (β −0.26, 95% CI −0.48–0.04, 
p = 0.020), total cholesterol (β −0.09, 95% CI −0.17–0.01, p = 0.033) and triglycerides (β 0.27, 95% CI 0.13–0.42, 
p = 0.005). LMR was independently associated with sex (β 0.27, 95% CI 0.17–0.37, p = 3.82 ∙ 10–6), age (β −0.02, 
95% CI −0.04 – 0.01, p = 0.035), systolic blood pressure (β 0.01, 95% CI 0.00–0.02, p = 0.022), hsCRP (β −0.05, 
95% CI −0.09–0.01, p = 0.012), triglycerides (β 0.08, 95% CI 0.01–0.15, p = 0.032) and NT-proBNP (β −0.05, 
95% CI −0.09–0.01, p = 0.006).
Clinical outcomes. No significant differences were observed in outcomes at one-year follow-up between 
women and men (Table 2). A higher LMR was significantly associated with lower peak CK-MB (β −0.27, 95% CI 
−0.50–0.03, p = 0.026) and lower peak troponin T (β −0.45, 95% CI −0.77–0.13, p = 0.006), also after adjustment 
for age and sex (Table 3). A higher LMR was also significantly associated with a lower mortality risk at one-year 
(HR 0.35, 95% CI 0.13–0.96, p = 0.042). The association between LMR and re-ACS showed a similar trend, 
although not statistically significant. There were no interactions between LMR and sex on outcome variables, 
also after adjustment hs-CRP and NT-proBNP as proxy for ischemic time. ROC area for LMR on mortality at one 
year was 0.395. This did not differ from the ROC areas for monocytes and lymphocytes on mortality separately 
(p = 0.532) (Supplemental Fig. 1 and 2).
Reproducibility in GIPS III study. We validated our findings using data from the GIPS-III trial. In line 
with our results, levels of lymphocytes were higher in women (2.2 ·109 cells/L, IQR 1.7·109–2.8·109 cells/L vs. 1.9·109 
cells/L, IQR 1.4–2.6 ·109 cells/L, p = 0.14, respectively). Additionally, women had a higher LMR compared to men 
(4.1, IQR 3.4–5.5 vs. 3.1, IQR 2.2–4.4, p = 1.63 ∙ 10–6). Monocyte count and percentage of monocytes were both 
increased in men (0.6·109 cells/L, IQR 0.5–0.8·109 cells/L vs. 0.5·109 cells/L, IQR 0.5–0.8·109 cells/L, p = 0.005; 
6.0%, IQR 4.9–7.3% vs. 5.3%, IQR 4.3–6.3%, p = 5.00 ∙ 10–4, respectively) (Supplementary Table 3).
After multivariate adjustment, sex remained significantly associated with lymphocyte count (β 0.24, 95% CI 
0.13–0.35, p = 3.14 ∙ 10–5), monocyte count (β −0.14, 95% CI −0.25–0.03, p = 0.016), percentage of monocytes (β 
−0.18, 95% CI −0.26–0.09, p = 9.40 ∙ 10–5), and LMR (β 0.39, 95% CI 0.26–0.53, p = 1.01 ∙ 10–8) (Supplementary 
Table 4).
There were no significant differences in outcome at one-year follow-up between women and men 
(Supplementary Table 5). A higher LMR was significantly associated with lower peak CK (β −0.31, 95% CI 
−0.60–0.03, p = 0.032) and lower peak CK-MB (β −0.27, 95% CI −0.53–0.01, p = 0.039), also after adjustment 
for age and sex (Supplementary Table 6). A trend was observed between higher LMR and decreased risk of 
re-ACS (HR 0.28, 95% CI 0.06–1.26, p = 0.098). In addition, after adjustment for age and sex, higher LMR was 
associated with smaller infarct size (β −0.026, 95% CI −0.05–0.01, p = 0.025). There was no association between 
LMR and LVEF. We did not observe interactions with sex on infarct size (biochemical and functional) or out-
comes at one-year follow-up.
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Characteristic Women Men P value
Total 147 (27) 405 (73)
Age, years 67 (12) 63 (12) 2.0 ∙ 10–4
BMI, kg/m2 26.5 (5.1) 27.2 (3.6) 0.110
Blood pressure, mmHg
Systolic 139.7 (27.8) 136 (23.6) 0.088
Diastolic 80.1 (14.8) 83.9 (15.5) 0.011
Heart rate, bpm 77 (18) 75 (18) 0.190
Cardiovascular risk factors
Smoking 0.001
Current smoker 65 (48%) 176 (46%)
Former smoker 12 (9%) 86 (23%)
Non-smoker 59 (43%) 119 (31%)
Hypertension 66 (47%) 153 (40%) 0.158
Hyperlipidemia 54 (39%) 128 (34%) 0.320
Diabetes 61 (15%) 27 (19%) 0.360
Family history 146 (42%) 51 (42%) 0.920
Stroke 7 (2%) 7 (5%) 0.045
Peripheral artery disease 14 (4%) 5 (3%) 0.980
Ischemia time 0.500
<2 hours 31 (23%) 94 (26%)
2–24 hours 93 (69%) 220 (62%)
24–72 hours 2 (2%) 11 (3%)
>72 hours 2 (2%) 7 (2%)
Unknown 6 (4%) 25 (7%)
Multi vessel disease 0.330
1 VD 58 (40%) 154 (38%)
2 VD 36 (24%) 128 (32%)
3 VD 45 (31%) 106 (26%)
No significant stenoses 8 (5%) 15 (4%)
Infarct-related artery TIMI flow grade
Before intervention 0.860
0 197 (56%) 67 (52%)
1 27 (7%) 9 (7%)
2 50 (14%) 21 (16%)
3 81 (23%) 32 (25%)
After intervention 0.430
0 6 (2%) 4 (3%)
1 5 (1%) 0 (0%)
2 23 (7%) 9 (7%)
3 319 (90%) 116 (90%)
Culprit vessel 0.004
LAD 49 (35%) 152 (41%)
RCA 71 (51%) 141 (38%)
LCX 11 (8%) 66 (18%)
Other 8 (5%) 15 (4%)
Primary PCI 118 (80%) 339 (84%) 0.345
Thrombolytic therapy 0 (0%) 0 (0%) NA
Laboratory values
HbA1c, mmol/L 5.8 (5.5, 6.2) 5.7 (5.4, 6.0) 0.002
CRP, mg/L 3.4 (1.6, 7.8) 2.2 (1.1, 4.7) 0.004
Total cholesterol, mmol/L 5.3 (4.4–6.0) 4.9 (4.3–5.7) 0.012
LDL-cholesterol, mmol/L 3.5 (3.0–4.2) 3.5 (2.8–4.3) 0.670
HDL-cholesterol, mmol/L 1.3 (1.1, 1.6) 1.1 (0.9, 1.3) 1.235 ∙ 10–11
Triglycerides, mmol/L 0.9 (0.6–1.3) 0.9 (0.6–1.5) 0.096
NT-proBNP, U/L 191 (84, 727) 109 (48, 311) 3.782 ∙ 10–6
Peak values
Continued
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Discussion
In this study of 552 patients presenting with STEMI, we were able to provide an elegant overview of the leukocyte 
profiles in women and men and observed sex differences. Women had higher lymphocyte counts, lymphocyte 
percentages, and a higher LMR, whereas men presented with higher percentages of monocytes and eosinophils. 
A higher LMR was associated with smaller infarct size and a lower mortality risk at one-year. These effects did not 
result in different outcomes between women and men.
The observed differences in activated lymphocytes, monocytes and eosinophils support previous research, 
where it has been shown that, after in vitro stimulation of peripheral blood mononuclear cells (PBMCs), women 
presented with higher numbers of activated and proliferating T-cells and B-cells in peripheral blood13,14. 
Furthermore, B-cell activation was higher in women measured by higher antibody responses, higher basal 
immunoglobulin levels and higher numbers of B-cells13. Sex hormones might play an important role in these 
observations as both T- and B-cells are known to have oestrogen receptors15. In line to this, hormonal depletion 
of androgens in male mice has shown to lead to higher numbers of T cells, suggesting a negative effect of male 
hormones on lymphocytes16.
We observed increased levels of monocytes in men. In vitro studies have shown that the number and function 
of monocytes in whole blood was higher in men versus women, after stimulation with lipopolysaccharide (LPS)17. 
The exact underlying mechanism has not been elucidated yet, but it has been suggested that monocytes in men 
are in a higher state of excitation compared to women17.
Limited is known about sex differences in eosinophils in STEMI patients. Previous research studied eosinophil 
levels in 620 STEMI patients and observed an association between a decrease in eosinophils and higher risk of 
major adverse events18. However, analyses were not stratified by sex. It is known that oestrogen regulates eosin-
ophil kinetics. In female mice greater eosinophilic infiltration into lung tissues has been observed, but the exact 
mechanisms underlying and whether this phenomenon is also present in post-menopausal women remains to 
be elucidated19.
Recently, it has been shown that leukocyte profiles differ across different ages in patients presenting with a 
STEMI20. Elderly STEMI patients presented with a higher acute pro-inflammatory profile (i.e. higher leuko-
cytes and neutrophil-to-lymphocyte ratio) compared to young patients. Furthermore, an increased inflamma-
tory response was associated with no-reflow and higher mortality post-STEMI. Another study showed that 
women younger than 71 years have a higher one-year mortality compared to the older women, whereas older 
women had a lower mortality compared to older men21. Our study is of additive value, since it provides a com-
prehensive overview of the leukocyte profiles directly after MI and their potential associations with outcome. 
Furthermore, we were able to reproduce our findings in a separate STEMI cohort of 379 patients and observed 
similar results. It is therefore of interest to further elucidate the interplay between the immune system, sex and 
age in STEMI patients.
In our study we showed that higher LMR was associated with smaller infarct size (biochemical and functional) 
and lower mortality. This is in accordance with previous literature, which found that a low LMR at 48 hours 
after admission was independently associated with both an increased short- and long-term mortality in STEMI 
patients22. It has been hypothesized that the association of lower LMR with higher mortality is due to an elevation 
of serum catecholamines and cortisol levels during a systemic stress response, resulting in lymphocyte apoptosis. 
This reflects a suppressed immune system. Others speculate on down-regulation of lymphocyte proliferation and 
differentiation, and lymphocyte redistribution within the lymphopoietic systems22.
Until now it is unknown whether the difference in LMR between women and men is also associated with 
different prognosis in both sexes. One would hypothesize that women have lower rates of re-events or mortality, 
since they have a higher LMR. In our study we did not observe different outcomes after one year between women 
and men. There was also no significant interaction between sex and LMR on clinical outcomes. Women, however, 
had higher CRP and NT-proBNP levels at baseline, which possibly reflects a longer ischemia time. Although the 
reported ischemia time was not different between men and women, there may be a discrepancy between real 
ischemia time and the one that is reported, as women with STEMI more often present with atypical symptoms 
which are not immediately recognized as ACS23. It is possible that such differences have partly affected the associ-
ation of LMR with clinical outcomes. However, after adjustment for ischemic time, hs-CRP and NT-proBNP, we 
still did not observe an interaction between LMR and sex on clinical outcome. Contrary to the categorical variable 
of ischemic time in the CardioLines population, we were able to investigate ischemic time more precisely in the 
GIPS-III study. Women had a slightly longer ischemic time (177 minutes vs. 156 minutes), but this difference was 
Characteristic Women Men P value
Peak CK, U/L 1042.5 (475, 1929) 1150 (464, 2772) 0.130
Peak CK-MB, U/L 130 (61.5, 243) 130.5 (51, 255) 0.670
Peak Troponin T, U/L 2376 (647, 5198) 2427 (827, 5951) 0.340
Table 1. Baseline characteristics CardioLines population. Data is expressed as number (%), as mean ± standard 
deviation (SD) for continuous variables with normal distributions and as median with inter-quartile range 
(IQR) for continuous variables with a skew distribution. BMI: Body Mass Index, CK: Creatine Kinase, CK-MB: 
Creatine kinase myocardial band, CRP: C-reactive protein, HbA1c: Glycated hemoglobin, HDL-cholesterol: 
High-density lipoprotein cholesterol, LDL-cholesterol: Low-density lipoprotein cholesterol, NT-proBNP: 
N-terminal pro brain natriuretic peptide, TIMI: Thrombosis In Myocardial Infarction, PCI: Percutaneous 
coronary intervention, VD: Vessel disease.
5Scientific RepoRtS |         (2020) 10:6851  | https://doi.org/10.1038/s41598-020-63185-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
not significant. Similarly, in the GIPS-III cohort, we did not find an interaction between LMR and sex on clinical 
outcomes either.
Another explanation could be the small number of events. Further research in a larger STEMI population is 
warranted to investigate the possible interaction between LMR and sex on clinical outcomes.
This study possess some limitations. First, this was a single-center study with very low adverse event rate dur-
ing the follow-up period. However, the already observed association between LMR and re-ACS invites to further 
investigate this association in a larger population. Second, we only had information on the quantity of the cells. 
It would be of value to also possess information on the functionality and activity of cells, and cytokine levels. 
Nevertheless, this study could serve as a starting point, providing new insights where to focus concerning new 
possible therapeutic targets.
Our study shows that women presented with higher lymphocyte count and LMR, whereas men had higher 
percentages of monocytes and eosinophils after a STEMI. A higher LMR was associated with smaller infarct size 
and a decreased mortality risk at one-year. However, this association was not different between sexes. Further 
research in a larger STEMI population is needed to investigate the possible interaction between leukocyte profile 
and sex on clinical outcomes.
Figure 1. Leukocyte profile in ST-elevation myocardial infarction patients given per sex. Data is expressed as 
median with inter-quartile range (red error bars). Significant differences are expressed with a p-value. LMR: 
lymphocyte to monocyte ratio.
Variable Women (N = 147) Men (N = 405) p value
No reflow post PCI 4 (2.7%) 11 (2.7%) 1.000
Re PCI 6 (4.1%) 12 (3.0%) 0.930
Re ACS 7 (4.8%) 10 (2.5%) 0.053
Death 3 (2.0%) 14 (3.5%) 0.390
Table 2. Outcome at one year follow-up (CardioLines population). ACS: Acute coronary syndrome, PCI: 
Percutaneous coronary intervention.
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Methods
Study population and design. The CardioLines biobank is a single-center, observational biobank aimed to 
study potential factors related to success or failure of diagnosis and treatment both from a patient as well as from 
a medical perspective24. The study protocol was in accordance with the Declaration of Helsinki and was approved 
by the local ethics committee (Groningen, the Netherlands) and national regulatory authorities. All methods 
were performed in accordance with the relevant guidelines and regulations. The current study is a substudy of 
the CardioLines biobank, including all STEMI patients with available baseline data and leukocyte profiling at 
admission between July 3rd, 2015, and November 23rd, 2017 (N = 552). Inclusion criteria were presentation with 
ST-elevation myocardial infarction (STEMI), according to the European Society of Cardiology guideline25, and 
age of 18 years or higher. Due to the acute nature of myocardial infarction, all participants included in the study 
initially provided verbal consent, and written informed consent was obtained at a later stage. Blood samples were 
collected at cardiac catheterization (T = 0). In case written informed consent could not be obtained due to early 
mortality, subjects were included by deferred consent. Ischemic time was defined as the time measured in hours 
from onset of complaints until cardiac catheterization. Variables regarded as prognostic outcomes after STEMI 
were and peak values of CK, CK-MB and Troponin T, no reflow post-PCI, re-PCI (defined as recurrent coronary 
intervention) within one-year after STEMI, re-ACS (defined as instable angina pectoris, non ST-segment eleva-
tion myocardial infarction, or STEMI) within one-year after STEMI, and death within one-year after STEMI. The 
definitions used have been described earlier26. No reflow post-PCI was defined as a Thrombosis In Myocardial 
Infarction (TIMI) grade of 0 and 1. In order to test the reproducibility of our findings, data from the glyco-
metabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction 
(GIPS-III) trial was used. This study was designed to evaluate the effect of metformin treatment on left ventricular 
function in 379 STEMI patients without known diabetes. Details on the design of the GIPS-III trial have been 
reported previously27.
Data collection. At admission, standard laboratory assessment was performed and standard physical exam-
ination parameters were measured according to protocol. LMR was computed as the lymphocyte count to mono-
cyte count measured at admission. Clinical follow-up was obtained from the central personal records database 
and hospital records, and if not available, with telephone contact..
Statistical analysis. Continuous variables with a normal distribution were summarized as mean ± stand-
ard deviation and continuous variables with a skewed distribution were presented as median with interquartile 
ranges. Discrete variables were presented as percentages. To compare groups between continuous normally dis-
tributed variables we used Student T-tests and the Mann-Whitney U test for skewed continuous variables. The 
Chi-square and Fisher exact test were used to compare groups between categorical variables. Univariate and 
multivariate linear and logistic regression analysis were applied to study associations between cell count and 
possible predictors. Cell counts significantly differing between both sexes at baseline were taken for univariate 
regression with covariates. If skewed, variables were log transformed. Age, sex, and variables with a P value less 
than 0.2 were included in multivariate regression analysis. Univariate linear and logistic regression analyses were 
performed to evaluate the association between LMR and peak CK, peak CK-MB, peak troponin T, and no reflow 
post-PCI. A Cox proportional hazard regression analysis was performed to study the association between LMR 
and re-PCI, re-ACS, and mortality at one year. We calculated receiver operating characteristic (ROC) curves for 
LMR, lymphocytes and monocytes on mortality at one year, using the De Long method. We also tested for inter-
action with sex. In the GIPS-III trial cardiac function has been determined by magnetic resonance imaging at 4 
months after MI. We tested whether LMR was associated with cardiac function. A two-sided P value less than 0.05 
was considered statistically significant for all analyses. Statistical analysis was performed using Stata version 15.0 
(StataCorp, College Station, Texas, USA).
Data availability
Data can be made accessible on request
Variable
Univariate regression Multivariate regression*
Coef./OR/HR 95% CI P value Coef./OR/HR 95% CI P value
Peak CK, log U/L −0.19 −0.44–0.05 0.120 −0.17 −0.43–0.08 0.178
Peak CK-MB, log U/L −0.02 −0.48–0.02 0.029 −0.27 −0.50–0.03 0.026
Peak Troponin T, log U/L −0.51 −0.81–0.20 0.001 −0.45 −0.77–0.13 0.006
No TIMI reflow post-PCI 0.96 0.29–3.05 0.939 0.96 0.29–3.21 0.952
Re- PCI (1 year) 0.67 0.23–1.92 0.458 0.54 0.18–1.61 0.271
Re-ACS (1 year) 0.30 0.09–1.00 0.051 0.28 0.08–1.01 0.052
Death (1 year) 0.28 0.10–0.76 0.013 0.35 0.13–0.96 0.042
Table 3. LMR as a predictor on outcome (CardioLines population). Coef: Coefficient, CI: Confidence interval, 
OR: Odds ratio, HR: Hazard ratio, ACS: Acute coronary syndrome, CK: Creatine kinase, CK-MB: Creatine 
kinase myocardial band, LMR: lymphocyte to monocyte ratio, PCI: Percutaneous coronary intervention. *After 
adjustment for age and sex.
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